We are live on ! Find out more
RC

Rangeley Capital Portfolio holdings

AUM $103M
1-Year Est. Return 77.32%
This Fund
S&P 500
This Quarter Est. Return
+28.51%
1 Year Est. Return
+77.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$31.8M
Cap. Flow
+$19.7M
Cap. Flow %
17.01%
Top 10 Hldgs %
43.17%
Holding
151
New
78
Increased
26
Reduced
12
Closed
24

Top Buys

Rank Stock Value
1
YEXT icon
Yext
YEXT
+$4.63M
2
TACO
Berto Acquisition Corp
TACO
+$3.29M
3
CCOI icon
Cogent Communications
CCOI
+$1.24M
4
LQDA icon
Liquidia Corp
LQDA
+$1.11M
5
ECHO
EchoStar
ECHO
+$1.04M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$6.66M
2
ITOS
iTeos Therapeutics
ITOS
+$3.01M
3
DK icon
Delek US
DK
+$2.79M
4
SKX
Skechers
SKX
+$2.27M
5
THRD
Third Harmonic Bio
THRD
+$1.57M

Sector Composition

Rank Sector Weight
1 Healthcare 32.16%
2 Financials 11.15%
3 Energy 9.32%
4 Communication Services 8.43%
5 Materials 7.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NERV icon
126
Minerva Neurosciences
NERV
$191M
$21.1K 0.02%
+10,000
New +$20.4K
VYNE icon
127
VYNE Therapeutics
VYNE
$19.1M
$16.8K 0.01%
+1,000
New +$32.7K
AKYA
128
DELISTED
Akoya BioSciences
AKYA
– –
-33,035
Closed -$42.9K
BPMC
129
DELISTED
Blueprint Medicines
BPMC
– –
-5,000
Closed -$641K
CRGX
130
DELISTED
CARGO Therapeutics
CRGX
– –
-41,851
Closed -$172K
ELEV
131
DELISTED
Elevation Oncology
ELEV
– –
-905,289
Closed -$332K
EPIX
132
DELISTED
ESSA Pharma
EPIX
– –
-170,000
Closed -$289K
HLVX
133
DELISTED
HilleVax
HLVX
– –
-153,790
Closed -$306K
ITOS
134
DELISTED
iTeos Therapeutics
ITOS
– –
-302,080
Closed -$3.01M
LITS
135
Lite Strategy Inc
LITS
$33.3M
– –
-10,000
Closed -$24.7K
SDEV
136
Stablecoin Development Corp
SDEV
$30.4M
– –
-6,642
Closed -$19.3K
NUVB icon
137
Nuvation Bio
NUVB
$2.25B
– –
-13,000
Closed -$25.4K
SAGE
138
DELISTED
Sage Therapeutics
SAGE
– –
-730,000
Closed -$6.66M
SEAT icon
139
Vivid Seats
SEAT
$87.5M
– –
-1,250
Closed -$42.3K
SKX
140
DELISTED
Skechers
SKX
– –
-36,000
Closed -$2.27M
SYBX
141
DELISTED
Synlogic
SYBX
– –
-13,597
Closed -$17.3K
TBPH icon
142
Theravance Biopharma
TBPH
$875M
– –
-33,729
Closed -$372K
THRD
143
DELISTED
Third Harmonic Bio
THRD
– –
-290,000
Closed -$1.57M
THTX
144
DELISTED
Theratechnologies
THTX
– –
-50,000
Closed -$118K
VERV
145
DELISTED
Verve Therapeutics
VERV
– –
-62,000
Closed -$696K
VIGL
146
DELISTED
Vigil Neuroscience
VIGL
– –
-67,800
Closed -$539K
WBA
147
DELISTED
Walgreens Boots Alliance
WBA
– –
-102,000
Closed -$1.17M
WOW
148
CALL
DELISTED
WideOpenWest
WOW
– –
-50,000
Closed -$203K
ZURA icon
149
Zura Bio
ZURA
$514M
– –
-21,000
Closed -$22.1K
MLACR
150
DELISTED
Mountain Lake Acquisition Corp Right
MLACR
– –
-30,000
Closed -$308K
3 4 5
6
7

Similar funds

EFT
Envision Financial Transparency Greensboro, North Carolina $103M AUM
GWL
Generations Wealth LLC Mason, Ohio $103M AUM
CC
Caspian Capital New York $103M AUM
ABLA
Alan B. Lancz & Associates Toledo, Ohio $103M AUM 31.99% 1-Year Est. Return
SPCM
Stoic Point Capital Management Palo Alto, California $103M AUM
OPAM
Olympus Peak Asset Management Greenwich, Connecticut $103M AUM 58.06% 1-Year Est. Return
ES
ETF Store Overland Park, Kansas $103M AUM 15.78% 1-Year Est. Return
IMT
Investment Management Trust Fitchburg, Massachusetts $103M AUM

Rangeley Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Rangeley Capital held 151 positions worth $116M, up 38% from $83.8M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Rangeley Capital deployed $19.7M of net new capital in Q3 2025, opening 78 new positions and adding to 26 existing holdings. Its largest new stake was Yext: 545,000 shares worth $4.64M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 47% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was Delek US, an estimated $2.79M trimmed.

  • Rangeley Capital's largest Q3 2025 buy was Yext: 545,000 shares worth $4.64M.
  • Rangeley Capital added most to GSR III Acquisition Corp in Q3 2025, an estimated $941K increase.
  • Rangeley Capital's biggest Q3 2025 reduction was Delek US, cutting an estimated $2.79M.
  • Rangeley Capital fully exited Sage Therapeutics in Q3 2025, selling an estimated $6.66M.
  • Rangeley Capital's ten largest holdings make up 43% of its $116M portfolio in Q3 2025.
  • Rangeley Capital opened 78 new positions and closed 24 in Q3 2025.
  • Rangeley Capital's portfolio value rose 38% quarter-over-quarter to $116M.

Based on Rangeley Capital's 13F filing for Q3 2025, filed 14 Nov 2025.